Treating Chronic Pain with Prescription Opioids in the Substance Abuser: Relapse Prevention and Management

Peggy Compton, RN, PhD, FAAN
UCLA School of Nursing
May 3, 2012

“Pleasure and pain, though directly opposite, are yet so contrived by nature as to be constant companions, and it is a fact that the same motions and muscles of the face are employed both laughing and crying.

Pierre Charron (1541 - 1603)

Pain                                         Pleasure
A Continuum of Sensation
Neuro-anatomical overlap of pain and reward

Early Response  Late Response

Key: Correlation Coefficient (r)  
- r = 0.5-0.5  
- r = 0.7-0.7

- Putative Reward Circuitry  
- Classic Pain Circuitry

Centrality of Opioid systems in both Pain and Reward responses

• Effects can be blocked with naloxone
• Binding induces second-messenger induced changes

Opioid Responses by Murine Strain

<table>
<thead>
<tr>
<th>Strain</th>
<th>BALB/c (common inbred)</th>
<th>CXBH (recombinant inbred)</th>
<th>C57 (common inbred)</th>
<th>CXBK (recombinant inbred)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pain Tolerance</td>
<td>↑ 2,4,6,8</td>
<td>↑ 4,6,7</td>
<td>↓ 1,2,4,6,9</td>
<td>↓ 3,5,12</td>
</tr>
<tr>
<td>Analgesic Response</td>
<td>↑ 3,4,6</td>
<td>↑ 3,5,5</td>
<td>↓ 1,2,4,6,7</td>
<td>↓ 3,5,12</td>
</tr>
<tr>
<td>Reinforcement/Reward Responses</td>
<td>↓ 2,4</td>
<td>↓ 1,2</td>
<td>↑ 4,10</td>
<td>↓ 2,4,10</td>
</tr>
<tr>
<td>Opioid Receptor Binding</td>
<td>↑ 1,2</td>
<td>↑ 2,8</td>
<td>↑ 4,12</td>
<td>↓ 3,12</td>
</tr>
</tbody>
</table>
Pain and Addiction As Interrelated Phenomena

Clinical implications for:
Treating Chronic Pain with Prescription Opioids in the Substance Abuser

- Can it be effective?
- Under what conditions is it effective?
- What nursing interventions underlie successful pain management?
- What if the patient is noncompliant/relapses?

“There are no randomized trials or controlled observational studies on the benefits and harms of opioids for chronic noncancer pain in patients with a history of substance abuse or addiction that are undergoing treatment for addiction” (2009, p. 52)

History of substance abuse in chronic pain patients

- Across literature, a personal or family history of substance use disorder is the best predictor of drug abuse, misuse or other aberrant drug-related behaviors
- Risk stratification approaches for selecting patients for chronic opioid therapy identify those with a history of substance use as at high risk for poor treatment response

(Chiu et al., 2009)
The patient with chronic pain AND untreated addictive disease WILL NOT get better with opioid prescription.

By definition, the addict will be unable to achieve the goal of chronic pain treatment, functional restoration:
- physical capabilities
- psychological intactness
- family and social interactions
- health care utilization
- appropriate medication use

Patients with active addiction are not candidates for opioid therapy.

---

**DSM-IV Substance Use Disorders**

**Substance Abuse**
- One or more within a 12-month period
  - Failure to fulfill major role obligation
  - Recurrent use in hazardous situations
  - Recurrent legal problems
  - Recurrent social or interpersonal problems

**Substance Dependence**
- Three or more within a 12-month period
  - Abuse criteria, plus:
    - Tolerance
    - Withdrawal
    - Larger amount/longer time than intended
    - Persistent desire to control use
    - Great deal of time spent in activities related to use

APA, 1994

---

**Addiction results in a “Syndrome of Pain Facilitation”**

(Schofferman & Savage, 1995)

Discomfort augmented by:
- subtle withdrawal syndromes
- intoxication or withdrawal-related sympathetic arousal, muscular tension
- concomitant health problems
- sleep disturbances
- affective changes
- functional changes
Pain Tolerance in Opioid and Cocaine abusers

(Compton, 1994)

Chronic Pain + Opioid Therapy

Improved functioning
- Opioid-responsive pain
- Absence of addiction

Unimproved functioning
- Opioid non-responsive pain
- Opioid-induced hyperalgesia
- Psychiatric Illness
- Addictive disease

Adapted from: Weaver & Schnoll. The Clinical Journal of Pain 2002 18:S61-S69

Patients with addictive disease in remission can appropriately and effectively use opioids for chronic pain

17%-26% of chronic pain patients have a substance dependence disorder in remission (Strain, 2002)

- Of a random sample of 300 veterans, 21% of those with chronic pain and on opioid therapy had a history of substance abuse, but no current indication of abuse or dependence (Clark, 2002).
- Of 52 chronic pain patients on opioid therapy, 27% had a history of addictive disease (50% w/ family history), but did not meet diagnostic criteria for a substance use disorder (Compton et al., 1998).
Addiction is a chronic disease

- Pathological basis
- Known risk factors
- Predictable course
- Treatments of known efficacy
  - Treatment requires behavioral changes
  - Most successful when treatment is ongoing
- Characterized by remissions and exacerbations
- Exacerbation = Relapse
  - precipitated by stressors (chronic pain, depression) and/or opioid exposure

Key goal of treating the substance abuser with chronic pain using controlled prescription drugs:

**Prevent Relapse**

- Assessment
  - What is the risk of relapse?
- Monitoring
  - How can relapse be identified?
- Management
  - How can chronic opioid treatment be provided to minimize risk of relapse?
  - How can relapse be managed?

Relapse

a well-understood phenomenon in addiction literature
Recovery is Cyclical, not Linear

Transtheoretical Model of Change
Prochaska & DiClemente, 1982

Stages of Change and Nursing Tasks

<table>
<thead>
<tr>
<th>Patient Stage</th>
<th>Motivational Tasks</th>
</tr>
</thead>
<tbody>
<tr>
<td>Precontemplation</td>
<td>Raise doubts; increase client’s perception of risks and problems</td>
</tr>
<tr>
<td>Contemplation</td>
<td>Tip the balance; evoke reasons for change and risks of not changing</td>
</tr>
<tr>
<td>Determination</td>
<td>Help pt to determine best plan of action</td>
</tr>
<tr>
<td>Action</td>
<td>Help pt to take steps toward change</td>
</tr>
<tr>
<td>Maintenance</td>
<td>Help pt to identify and use strategies to prevent relapse</td>
</tr>
<tr>
<td>Relapse</td>
<td>Renew process of contemplation while maintaining self-esteem</td>
</tr>
</tbody>
</table>
Relapse: Competing Definitions

- “treatment failure”
- all-or-none outcome
- an end state
- nothing much one can do about it
- overpowers the individual

“fork in the road to change”
- part of the process
- a mistake; a slight error; a slip
- a useful, beneficial step
- a learning opportunity

Goals of Relapse Prevention

In general:
- Develop new behaviors (success is more than not engaging in unhealthy behavior)
- Learn to monitor signs of vulnerability to relapse (recognize “high risk” situations)
- Establish strategies to deal with craving (enhance coping responses) and relapse

For pain patient:
- Optimal functioning with appropriate opioid use

High Risk Situations

Similar across behaviors:
- alcoholics, smokers, heroin addicts, gamblers, overeaters

56% intrapersonal determinants:
- negative or positive emotional/physical states
- craving/urges

44% interpersonal determinants:
- interpersonal conflicts, social pressure
- stress

* For pain patients: unrelieved pain, opioid withdrawal Sx

Goal is to increase self-efficacy in high risk situations
1. Identify High-risk Situations

Behavioral assessment procedures
- an awareness and intervention technique self-monitoring & direct observation
  • actual use, urges/cravings, intentions to use, coping mechanism used
  • thwarts automaticity of the behavior
- self-efficacy ratings - coping capacity in high risk situations
- review past relapse episodes/relapse fantasies

2. Enhance Coping Responses

High-risk Situational Cues = Discriminative Stimuli ("red flags")
- avoidance
- skill training and practice
  • advance planning; problem-solving
- relapse rehearsal
- relaxation training
- stress management
  • Lifestyle balance – new behaviors
- Treat psychiatric disorders

Craving
- Intense powerful drive or desire
- Difficult to control
- Common source of relapse

Coping with Craving
- Distraction
- Talking about craving
- Active recall of negative consequences
- Using self-talk
3. Minimize Extent of Lapse

Prevent lapse from developing into full-blown relapse (and loss from treatment)
- Develop a “relapse contract” – put stops in place
- Balance positive outcome expectancies (immediate gratification) with delayed effects
- Cognitive restructuring
  - avoid the abstinence violation effect

The Relapse Process

Relapse Analysis

- Session to be done when relapse occurs after a period of good behavior
- Functional analysis
  - What happened?
  - How did you feel?
- Relapse should be framed as learning experience for client
Key goal of treating the substance abuser with chronic pain using controlled prescription drugs:

**Prevent Relapse**

- Assessment
  - What is the risk of relapse?
- Monitoring
  - How can relapse be identified?
- Management
  - How can chronic opioid treatment be provided to minimize risk of relapse?
  - How can relapse be managed?

**Assessment of risk for relapse**

**Status of disease remission:**

- How long has patient been in recovery? What is current status of addiction recovery efforts/treatment?
- What type(s) of drugs were abused?
- What are current stressors that might precipitate relapse? (i.e., unrelieved pain; withdrawal Sx; psychiatric Sx)
- What are current protective factors against relapse? (i.e., coping responses)
- How stable does patient feel in recovery? (i.e., relapse contract)

**Assessment of risk for relapse**

Correlates of analgesic abuse in chronic pain patients with a history of addiction:

- Absence of family support
- Lack of 12-step involvement
- Recent history of polysubstance abuse (not alcohol abuse alone)
- Previous history of chronic opioid therapy
- Failure in improvement of pain symptoms

(Dunbar & Katz, 1996)
Monitoring for emergence of relapse

Like constipation and sedation, behaviors consistent with relapse must be assessed as a potential medication-related adverse effect.

Evidence of addiction in pain patients on opioid therapy
- Adverse consequences associated with opioid use
- Loss of control over the use of opioids
- Preoccupation with obtaining opioids
- Decline in function

2001 Consensus Statement from the American Society of Addiction Medicine, American Academy of Pain Medicine, and the American Pain Society

Monitoring Medication Use behaviors

- Addiction is a disease of behavior
  - Patient behavioral response to the opioid-analgesic regimen provides evidence for the presence of active addiction.
- Objective evidence of medication use behaviors
  - Treatment contracts/medication agreements
  - Urine toxicology

Opioid treatment contracts

- Evidence that the patient is having difficulty adhering to prescribed medication regimen
  - Outline inappropriate or aberrant medication-use behaviors
  - Not a specific indicator of relapse to addictive disease
- For patient with history of substance abuse
  - Emphasize urine toxicology
  - Add engagement in recovery efforts
  - Put controls in place with respect to opioid access
  - Add relapse plan
Noncompliance

Lying about drug use

Signs of drug misuse

Emotional/psychiatric issues

Poor medication response

Medication misuse ≠ Addiction

• Hariharan et al. (2007): 17% of opioid contracts cancelled by physician
  – 10% due to illicit urine toxicology (cocaine, cannabis)
  – 5% due to abuse prescription opioid use
  – 2% rule violation
• Compton et al. (2008): 28% discharged for medication misuse behaviors
  – 8% due to misuse of opioids
∴ Only 1/3 of those discharged from pain treatment were misusing/abusing opioids

“Problematic” prescription opioid use

Detailed pain work-up + ↑ opioid dose

Improved functioning/ Absence of toxicity OR Unimproved functioning/ Presence of toxicity

Therapeutic dependence

Pseudoaddiction

Non-opioid responsive pain

Consider addictive disease

Adapted from Weaver & Schnoll The Clinical Journal of Pain 2002 18:S61-S69.
Pain Characteristics and Opioid Analgesic response in Addiction

<table>
<thead>
<tr>
<th>Differential Dx</th>
<th>Nature of pain</th>
<th>Onset</th>
<th>Response to opioid administration</th>
<th>Type of previous opioid used</th>
</tr>
</thead>
<tbody>
<tr>
<td>Increased pain pathology</td>
<td>Localized to pain site</td>
<td>Variable</td>
<td>Pain improves</td>
<td>Neither</td>
</tr>
<tr>
<td>Opioid tolerance</td>
<td>Localized to pain site</td>
<td>Gradual</td>
<td>Pain improves</td>
<td>Long acting</td>
</tr>
<tr>
<td>Opioid withdrawal</td>
<td>Diffuse, hyperalgesia</td>
<td>Abrupt</td>
<td>Pain improves</td>
<td>Short acting</td>
</tr>
<tr>
<td>Opioid-induced hypertension</td>
<td>Diffuse, hyperalgesia</td>
<td>Abrupt or Gradual</td>
<td>Pain worsens</td>
<td>Short acting</td>
</tr>
<tr>
<td>Pseudo-addiction</td>
<td>Localized to pain site</td>
<td>Ongoing</td>
<td>Pain improves</td>
<td>either</td>
</tr>
<tr>
<td>Addictive disease</td>
<td>Diffuse, hyperalgesia</td>
<td>Ongoing</td>
<td>Pain worsens</td>
<td>Short acting</td>
</tr>
</tbody>
</table>

Management

**Support recovery**
- Regular and thoughtful urine toxicology
- Ongoing assessment of substance abuse treatment
- Ongoing assessment and management of psychiatric disorders
- Ongoing assessment of life or pain-related stressors
- Avoid opioid withdrawal

**Be prepared for it’s emergence**
- Prescriber of opioids for chronic use is accountable for having a management strategy in place if relapse occurs.
- Providing daily opioids without suitable addiction expertise or support in place puts both the pain-management practitioner and patient at risk for poor outcomes.
- If unable to manage these adverse effects themselves, clinician should knowledgeably refer patients to qualified specialists who can better treat the untoward response.
Management

Don’t just discharge

• Relapse provides an opportunity to intervene in the progression of addictive disease***
• Goal is a thoughtful and working partnership between addiction and pain specialists
  – pain practitioner continuing treatment for pain while also supporting addiction treatment
• As opposed to discharge, it is incumbent upon the pain-management practitioner to take more of an advocacy role in the management of addiction

Does pain protect patient from addiction responses?

Under acute pain conditions:
• Significantly less morphine analgesic tolerance in pain assays
• Significantly less morphine physical withdrawal symptoms (Brown et al., 2002, Vaccarino et al., 1993)
• Significantly less opioid reward or euphoria (Zacny et al., 1996)
Remission of Addictive Disease Improves Pain and Functionality

- Ability to comply with regimes
- Enhanced cognitive skills
- Behavior modification techniques
- Improved social support
- Management of neuropsychiatric complications
- Improved stress control

Settings in which nurses encounter pain and addiction

- Pain clinics
- Addiction clinics
- Post operative units
- Emergency room
Interventions for Chronic disease management

- Motivational interviewing
- Cognitive behavior therapy
- Psychiatric assessment
- Stress management
- Functional Assessment

What does nursing bring to the field of pain and chemical dependency?

- Growing literature
- Presence across clinical setting
- Complex, holistic perspective of patient
- Chronic disease management
- Independent nursing interventions
- Patient advocacy

THANK YOU!

Presenter Contact Details:
Peggy Compton RN, PhD, FAAN
Associate Dean and Professor
UCLA School of Nursing
Los Angeles CA USA 90095
1 310 206-2625 (office phone)
1 310 794-7462 (fax)
pcompton@sonnet.ucla.edu
Relapse Analysis Topics

- Overview of the concept; things don’t “just happen”
  - Re-emergence signals relapse risk (“it’s a duck”)
- Relapse Justification
  - Recognize and stop
- Dangerous Emotions
  - Loneliness, anger, deprivation
- Be Smart, not Strong
  - Avoid the dangerous people and places
- Avoiding Relapse Drift
  - Identify “mooring lines”
  - Monitor drift

---

Table 1. Failure Affecting Drug Detection in Urine Toxicology Analysis

<table>
<thead>
<tr>
<th>Substance</th>
<th>Screening Limit</th>
<th>Confirmation Limit</th>
<th>Duration of Detection</th>
<th>False Positives</th>
</tr>
</thead>
<tbody>
<tr>
<td>Methadone</td>
<td>100 ng/mL</td>
<td>100 ng/mL</td>
<td>72 h</td>
<td>—</td>
</tr>
<tr>
<td>Opiates</td>
<td>50 ng/mL</td>
<td>100 ng/mL</td>
<td>24 h</td>
<td>—</td>
</tr>
<tr>
<td>Cocaine</td>
<td>10 ng/mL</td>
<td>25 ng/mL</td>
<td>24 h</td>
<td>—</td>
</tr>
<tr>
<td>Phencyclidine (PCP)</td>
<td>5 ng/mL</td>
<td>25 ng/mL</td>
<td>24 h</td>
<td>—</td>
</tr>
</tbody>
</table>

Table 2. Interpretation of Opioid Toxicology in Pain Patients

<table>
<thead>
<tr>
<th>Opioid</th>
<th>Interpretation</th>
<th>Metabolite</th>
<th>Toxicology Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Codeine</td>
<td>Morphinelike</td>
<td>Hydrocodeine</td>
<td>≥ 10 µg/mL</td>
</tr>
<tr>
<td>Hydrocodeine</td>
<td>Hydrocodeine</td>
<td>Hydrocodeine</td>
<td>≥ 10 µg/mL</td>
</tr>
<tr>
<td>Diamorphine</td>
<td>Morphinelike</td>
<td>Morphinelike + hydrocodeine</td>
<td>≥ 10 µg/mL</td>
</tr>
<tr>
<td>Mephenoxylane</td>
<td>Morphinelike</td>
<td>Mephenoxylate + hydrocodeine</td>
<td>≥ 10 µg/mL</td>
</tr>
<tr>
<td>Hydromorphone</td>
<td>Morphinelike</td>
<td>Hydrocodeine</td>
<td>≥ 10 µg/mL</td>
</tr>
<tr>
<td>Methadone</td>
<td>Morphinelike</td>
<td>Hydrocodeine</td>
<td>≥ 10 µg/mL</td>
</tr>
<tr>
<td>Tramadol</td>
<td>Morphinelike</td>
<td>Morphinelike + hydrocodeine</td>
<td>≥ 10 µg/mL</td>
</tr>
</tbody>
</table>

Table 3. Recommended Guidelines for the Use of Urine Toxicology

1. Adopt a universal precautions approach.
2. Include urine toxicology testing as part of the opioid treatment agreement.
3. Collect urine samples on a random basis.
5. Consider the age of the patient.
7. Consider the setting of treatment.
8. Use an automated system.
9. Use a commercial laboratory.
10. Use a reliable laboratory.

---

Sources: Achy & Beasley, 2004; Oates, 2005; Gurney et al., 2005; Nielson et al., 2005; Reznik & Perlis, 2001; Substance Abuse and Mental Health Services Administration, 2000.
IntNSA Webinar Series

Funding for this webinar was made possible (in part) by (1H79T1022022) from SAMHSA. The views expressed in written webinar materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.